These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21275037)

  • 21. Industry sponsorship in research and publishing: who is really to blame for perceived bias?
    Amsden GW
    Ann Pharmacother; 2004 Apr; 38(4):714-6. PubMed ID: 14982974
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical trials in Norway--completion and reporting are not satisfactory].
    Sandaker L; Fjeld B; Reikvam A; Lislevand H; Madsen S
    Tidsskr Nor Laegeforen; 2004 Nov; 124(22):2888-90. PubMed ID: 15550958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? Yes.
    Goldacre B
    BMJ; 2009 Nov; 339():b4949. PubMed ID: 19946143
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of the unblinded sponsor statistician.
    Snapinn S; Cook T; Shapiro D; Snavely D
    Stat Med; 2004 May; 23(10):1531-3. PubMed ID: 15122733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Note from the editor.
    Freedman R
    Am J Psychiatry; 2010 Nov; 167(11):1407. PubMed ID: 21041255
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
    James JS
    AIDS Treat News; 1998 Mar; (No 290):8. PubMed ID: 11365123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is academic medicine for sale?
    Firlik AD; Lowry DW
    N Engl J Med; 2000 Aug; 343(7):509-10. PubMed ID: 10950674
    [No Abstract]   [Full Text] [Related]  

  • 28. [Ghostwriting].
    Haug C
    Tidsskr Nor Laegeforen; 2008 May; 128(9):1039. PubMed ID: 18451881
    [No Abstract]   [Full Text] [Related]  

  • 29. Challenges in science and academic-industry interactions.
    Eisman JA; Lorenzo JA
    J Bone Miner Res; 2007 Nov; 22(11):1654-5. PubMed ID: 17931099
    [No Abstract]   [Full Text] [Related]  

  • 30. Implications of pharmaceutical industry funding on clinical research.
    Lexchin JR
    Ann Pharmacother; 2005 Jan; 39(1):194-7. PubMed ID: 15562137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment by human research ethics committees of potential conflicts of interest arising from pharmaceutical sponsorship of clinical research.
    Newcombe JP; Kerridge IH
    Intern Med J; 2007 Jan; 37(1):12-7. PubMed ID: 17199839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry.
    Winther FO; Hole OP; Nitter-Hauge S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):909-12. PubMed ID: 17673994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small study on industry trial sponsorship leads to big questions about quality and bias.
    Twombly R
    J Natl Cancer Inst; 2007 Jul; 99(13):988-90. PubMed ID: 17596566
    [No Abstract]   [Full Text] [Related]  

  • 34. [The journals must honestly tell who is doing the job].
    Bergström R
    Lakartidningen; 2008 May 7-13; 105(19):1406-7. PubMed ID: 18574981
    [No Abstract]   [Full Text] [Related]  

  • 35. Ethical issues in the relationships involving medicine and industry.
    Thomas PS; Tan KS; Yates DH
    Intern Med J; 2005 Dec; 35(12):732. PubMed ID: 16313554
    [No Abstract]   [Full Text] [Related]  

  • 36. Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? No.
    Lawton V
    BMJ; 2009 Nov; 339():b4953. PubMed ID: 19946144
    [No Abstract]   [Full Text] [Related]  

  • 37. [More stringent requirements concerning manuscripts. Declarations of potential connections and conflicts of interest published in the Lakartidningen].
    Milerad J; Ahlberg J; Eliasson M; Fridén B; Håkansson A; Sundberg CJ; Agren H; Ostergren J
    Lakartidningen; 2002 Apr; 99(15):1662-3. PubMed ID: 12025190
    [No Abstract]   [Full Text] [Related]  

  • 38. The sins of ghostwriting.
    Somberg JC
    Am J Ther; 2008; 15(4):297-8. PubMed ID: 18645328
    [No Abstract]   [Full Text] [Related]  

  • 39. Commentary: Professional responsibilities.
    Jacobs A
    Pharm Stat; 2011; 10(1):82. PubMed ID: 21275039
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical research and pharmaceutical industry. A relationship with advantages and disadvantages].
    ten Cate JW; Büller HR
    Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1572-6. PubMed ID: 10443284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.